DARZALEX Q1 2026 sales hit $3.96B for Genmab (NASDAQ: GMAB)
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S reports that worldwide net trade sales of DARZALEX (daratumumab), as reported by Johnson & Johnson, reached USD 3,964 million in the first quarter of 2026. Net trade sales were USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world.
Genmab receives royalties on these global DARZALEX sales under its exclusive worldwide license agreement with Johnson & Johnson to develop, manufacture and commercialize daratumumab.
Positive
- None.
Negative
- None.
Key Figures
DARZALEX worldwide net trade sales: USD 3,964 million
DARZALEX U.S. net trade sales: USD 2,208 million
DARZALEX rest-of-world net trade sales: USD 1,756 million
3 metrics
DARZALEX worldwide net trade sales
USD 3,964 million
First quarter of 2026, reported by Johnson & Johnson
DARZALEX U.S. net trade sales
USD 2,208 million
First quarter of 2026, U.S. market
DARZALEX rest-of-world net trade sales
USD 1,756 million
First quarter of 2026, outside the U.S.
Key Terms
net trade sales, royalties, exclusive worldwide license, antibody–drug conjugates (ADCs), +1 more
5 terms
net trade sales financial
"worldwide net trade sales of DARZALEX (daratumumab) ... were USD 3,964 million"
royalties financial
"Genmab receives royalties on the worldwide net sales of DARZALEX"
Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.
exclusive worldwide license financial
"under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab"
antibody–drug conjugates (ADCs) technical
"including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies"
forward looking statements regulatory
"The Company Announcement contains forward looking statements."
Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF APRIL 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated April 14, 2026 | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: April 14, 2026
Exhibit 99.1
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Company Announcement
•Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 million
•Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)
COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,964 million in the first quarter of 2026. Net trade sales were USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. DARZALEX® and DARZALEX FASPRO® are trademarks of Johnson & Johnson. DARZALEX® and DARZALEX FASPRO® are trademarks of Johnson & Johnson.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 22 Page 1/1 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
FAQ
What DARZALEX sales did Genmab (GMAB) disclose for Q1 2026?
Genmab reported worldwide net trade sales of DARZALEX of USD 3,964 million in Q1 2026. Johnson & Johnson reported these figures, covering both intravenous and subcutaneous formulations, and Genmab earns royalties on this global revenue under its license agreement.
How were DARZALEX Q1 2026 sales for Genmab (GMAB) split by region?
DARZALEX net trade sales in Q1 2026 were USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world. These regional figures were reported by Johnson & Johnson and form the basis for Genmab’s royalty income.
How does Genmab (GMAB) earn money from DARZALEX sales?
Genmab earns royalties on worldwide net sales of DARZALEX from Johnson & Johnson. Under an exclusive worldwide license, J&J develops, manufactures and commercializes daratumumab, while Genmab benefits financially through ongoing royalty payments tied to global product sales.
Which DARZALEX products are covered by Genmab’s royalty agreement?
The royalty agreement covers both intravenous DARZALEX and the subcutaneous DARZALEX FASPRO formulation. Johnson & Johnson records worldwide net trade sales for these products, and Genmab receives royalties based on those combined global sales each period.
What type of company is Genmab (GMAB) and what does it focus on?
Genmab is an international biotechnology company focused on innovative antibody medicines for cancer and other serious diseases. Its science underpins eight approved antibody medicines and a late-stage pipeline, including bispecific antibodies, antibody–drug conjugates and other next-generation antibody formats.
Who holds the commercial rights to DARZALEX in Genmab’s collaboration?
Johnson & Johnson, through Janssen Biotech, Inc., holds exclusive worldwide rights to DARZALEX. Under this license, J&J develops, manufactures and commercializes daratumumab, while Genmab’s economic interest comes from royalties on worldwide net sales reported by J&J.